dc.contributor.author | Pugh, SA | |
dc.contributor.author | Bowers, M | |
dc.contributor.author | Ball, A | |
dc.contributor.author | Falk, S | |
dc.contributor.author | Finch-Jones, M | |
dc.contributor.author | Valle, JW | |
dc.contributor.author | O'Reilly, DA | |
dc.contributor.author | Siriwardena, AK | |
dc.contributor.author | Hornbuckle, J | |
dc.contributor.author | Rees, M | |
dc.contributor.author | Rees, C | |
dc.contributor.author | Iveson, T | |
dc.contributor.author | Hickish, T | |
dc.contributor.author | Maishman, T | |
dc.contributor.author | Stanton, L | |
dc.contributor.author | Dixon, E | |
dc.contributor.author | Corkhill, A | |
dc.contributor.author | Radford, M | |
dc.contributor.author | Garden, OJ | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Maughan, TS | |
dc.contributor.author | Bridgewater, JA | |
dc.contributor.author | Primrose, JN | |
dc.date.accessioned | 2017-03-27T12:32:54Z | |
dc.date.issued | 2016-08 | |
dc.identifier.citation | British journal of cancer, 2016, 115 (4), pp. 420 - 424 | |
dc.identifier.issn | 0007-0920 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/535 | |
dc.identifier.eissn | 1532-1827 | |
dc.identifier.doi | 10.1038/bjc.2016.208 | |
dc.description.abstract | Background The addition of cetuximab (CTX) to perioperative chemotherapy (CT) for operable colorectal liver metastases resulted in a shorter progression-free survival. Details of disease progression are described to further inform the primary study outcome.Methods A total of 257 KRAS wild-type patients were randomised to CT alone or CT with CTX. Data regarding sites and treatment of progressive disease were obtained for the 109 (CT n=48, CT and CTX n=61) patients with progressive disease at the cut-off date for analysis of November 2012.Results The liver was the most frequent site of progression (CT 67% (32/48); CT and CTX 66% (40/61)). A higher proportion of patients in the CT and group had multiple sites of progressive disease (CT 8%, 4/48; CT and CTX 23%, 14/61 P=0.04). Further treatment for progressive disease is known for 84 patients of whom 69 received further CT, most frequently irinotecan based. Twenty-two patients, 11 in each arm, received CTX as a further line agent.Conclusions Both the distribution of progressive disease and further treatment are as expected for such a cohort. The pattern of disease progression seen is consistent with failure of systemic micrometastatic disease control rather than failure of local disease control following liver surgery. | |
dc.format | Print-Electronic | |
dc.format.extent | 420 - 424 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Colorectal Neoplasms | |
dc.subject | Liver Neoplasms | |
dc.subject | Disease Progression | |
dc.subject | Organoplatinum Compounds | |
dc.subject | Camptothecin | |
dc.subject | Leucovorin | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Disease-Free Survival | |
dc.subject | Neoadjuvant Therapy | |
dc.subject | Hepatectomy | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Metastasectomy | |
dc.subject | Capecitabine | |
dc.subject | Cetuximab | |
dc.subject | Irinotecan | |
dc.subject | Oxaliplatin | |
dc.title | Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-06-13 | |
rioxxterms.versionofrecord | 10.1038/bjc.2016.208 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-sa/4.0 | |
rioxxterms.licenseref.startdate | 2016-08 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | British journal of cancer | |
pubs.issue | 4 | |
pubs.notes | 12 months | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 115 | en_US |
pubs.embargo.terms | 12 months | |
icr.researchteam | Medicine (RMH Smith Cunningham) | en_US |
dc.contributor.icrauthor | Cunningham, David | |